Top Life Sciences & BioTech Companies by Revenue 2026

Encapsulate Bio develops tumor-on-a-chip microfluidic platforms that test patient-derived tumor samples against cancer therapies to guide personalized treatment selection; early-stage biotech focused on ex vivo drug sensitivity testing for oncology.

Uncommon Bio (formerly Higher Steaks) pivoted from cultivated pork to therapeutic biomanufacturing in 2024–2025; its cultivated meat platform was acquired by Meatable in 2025; now focuses on scalable cell biology tools for human health applications.

Loyal is a veterinary biotech developing FDA-regulated longevity drugs for dogs; its lead drug LOY-001 received FDA reasonable expectation of effectiveness — the first longevity drug for any species to do so; raised $45M; founded by Celine Halioua.

Lightship is a clinical research organization (CRO) specializing in decentralized and hybrid clinical trial design, combining in-clinic visits, at-home appointments, mobile research units, and digital health tools to improve participant access and.

DNA Script has raised $335M total including a $165M oversubscribed Series C; received CE Mark in 2025 for SYNTAX System in clinical labs across Europe; developing enzymatic DNA synthesis printers that enable on-demand, benchtop DNA production for.

Huisheng Pharmaceutical is a Chinese pharma company specializing in traditional Chinese medicine and modern drug formulations; operates across R&D, manufacturing, and distribution; serves domestic and international markets from its base in China.

Precision oncology company emerged from stealth Apr 2026 with $100M oversubscribed Series A co-led by RA Capital and a16z Bio; Pointillist platform identifies novel tumor-specific epitopes for antibody-drug conjugates beyond existing ADC targets.

Florence Healthcare is the leading clinical trial site enablement platform, connecting 12,000+ research sites in 45 countries; $116M raised from Insight Partners; processes 6.5M+ research workflows monthly via remote digital document management.

Drug discovery company founded by Daphne Koller integrating ML with high-throughput biology; raised $400M+ to build proprietary biological datasets for predicting drug targets and clinical outcomes in neurology, metabolic, and oncology programs.

Full-stack AI biologics company raised $787M in Mar 2026 backed by Sanofi, Pfizer/Hillhouse, and DST Global; $2.56B Sanofi collaboration signed Jan 2026; platform generates 40+ AI-designed protein therapeutics across multiple therapeutic areas.

Outpace Bio is a clinical-stage biotech using AI-powered protein design and synthetic biology to develop next-generation cell therapies targeting solid tumors; founded by pioneers in CAR-T and protein engineering; raised $109M Series B in 2024;

Advanced Microbubbles develops ultrasound-activated microbubble technology for targeted drug and gene delivery, with a primary focus on oncology; microbubbles encapsulate therapeutic agents and release them precisely at tumor sites via focused.

Relation Therapeutics uses its Lab-in-the-Loop AI platform to discover novel drug targets; secured a $1.7B multi-program Novartis collaboration and a $200M+ GSK partnership; raised $26M additional funding from NVIDIA Ventures in December 2025.

YC-backed AI company raised $48M Series A co-led by a16z Bio and GV in Feb 2026; builds digital twins of human physiology to generate diverse synthetic clinical trial populations, addressing chronic underrepresentation of women and minorities.

BenchSci is an AI-powered biomedical research intelligence platform used by 16 of the top 20 pharma companies; accelerates experiment design by analyzing millions of scientific papers and proprietary data to recommend validated reagents and.

Frontier Bio develops living vascular grafts and bioprinted human tissue for pharmaceutical testing and future organ donation, using a 4D self-assembly approach to create complex lung, brain, and vascular microtissues without animal testing.

AI protein design company released OpenCRISPR-1, the first gene editor designed entirely by AI; raised $35M developing novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space beyond what evolution has produced.

DNAnexus is the leading precision health data cloud, managing 65+ petabytes of biomedical data for 12,000+ users across 48 countries; $200M Series I led by Blackstone Growth; serves 7 of top 10 pharma and 8 of top 10 diagnostics companies.

Numerion Labs (fka Atomwise) deploys AtomNet deep learning for ultra-fast virtual drug screening; partnered with Sanofi for up to $1.2B in milestones; rebranded Oct 2025 with new APEX platform for hyper-scalable virtual library screening.

LinusBio is a precision medicine company using AI-powered exposome sequencing of hair samples to detect environmental and genetic disease risk factors; focuses on early autism detection; spun out of MIT; raised $12.5M in Series A funding.

Inceptive designs synthetic RNA molecules for therapeutic applications using deep learning and high-throughput experiments; targets mRNA medicines, RNA-based vaccines, and gene regulation; raised $100M Series A led by Andreessen Horowitz;

Shorla Oncology is a specialty pharma focused on oncology and rare/pediatric cancers; reformulates approved therapies to address drug shortages; raised $27M Series A in 2022; markets FDA-approved Enrylaze (asparaginase) in the US and EU.

Circle Pharma develops orally deliverable macrocycle drug candidates targeting intracellular protein-protein interactions in cancer; raised $90M Series B in 2023 led by Novo Holdings and Foresite Capital; headquartered in San Francisco;

GenScript ProBio is the CDMO subsidiary of GenScript Biotech, offering gene synthesis, biologics development, cell therapy manufacturing (CAR-T), and life science CRO services; publicly listed on the Hong Kong Stock Exchange (HK: 1548);

Kumquat Biosciences is an oncology-focused drug discovery company developing novel cancer therapeutics through internal research programs and academic collaborations; early-stage biotech with undisclosed funding; based in San Francisco.

Kriya Therapeutics is a gene therapy company using AAV vector engineering to develop one-time treatments for chronic diseases including diabetes and hemophilia; raised $270M total including a $150M Series C in 2022 led by Premji Invest;

Orca Bio is developing high-purity precision cell therapies using proprietary cell sorting technology to improve the safety and outcomes of bone marrow transplantation; raised $270M+; lead programs in AML, MDS, and other blood cancers;

Prolific Machines is a Berkeley-based biotech company using light to control cell growth and differentiation, dramatically reducing bioreactor costs for cultivated meat and cell therapy; raised $55M+ including a $36M Series B in 2023;

Persephone Biosciences uses gut microbiome profiling and synthetic biology to develop cancer immunotherapy response predictors and novel therapeutics; founded 2017 in San Diego; received BARDA funding for microbiome-based diagnostics;

Largest-funded pure-play longevity startup raising $1B Series A at $5B valuation; Sam Altman-backed; pursuing cellular reprogramming, autophagy, and plasma factor therapeutics in parallel; first human trial targeting Australia launch.

Evolved by Nature has developed Activated Silk technology — a green chemistry platform using natural silk proteins as sustainable, high-performance ingredients for textiles, personal care, and medical applications; raised over $120M;

Alzheon is a clinical-stage biotech developing ALZ-801, an oral amyloid oligomer inhibitor for Alzheimer's disease prevention in genetically at-risk patients; has completed Phase 2b/3 trials; raised over $100M; pursuing FDA approval.

Evozyne applies generative AI and evolutionary principles to design novel therapeutic proteins; raised $144M total including $81M Series B led by Fidelity and OrbiMed with NVIDIA NVentures participation; 54 employees; Chicago-based.

Delfi Diagnostics has raised $332M total to develop blood-based cancer detection using whole-genome cfDNA fragmentation analysis and ML; clinically validated FirstLook Lung test; partnering with Hackensack Meridian Health in 2025;

Elligo Health Research brings clinical trials into healthcare settings by using EHR data for patient identification and providing site infrastructure; enables physicians to conduct trials without becoming dedicated research sites;

BostonGene is an AI-powered precision oncology company using multiomics and tumor microenvironment analysis to guide cancer treatment; won Frost & Sullivan's 2025 Global Tech Innovation Award and partnered with Johnson & Johnson.

Freenome is a biotech company developing AI-powered multiomics blood tests for early cancer detection; raised $1.1B+ total with Roche as a major investor; signed a $75M exclusive license with Exact Sciences for colorectal cancer;

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

Cerevance is a CNS drug discovery company using proprietary NETSseq single-nucleus transcriptomics to identify cell-type-specific drug targets in human brain tissue; lead program CVN424 for Parkinson's disease completed Phase 2;

Mammoth Biosciences is a CRISPR gene editing company co-founded by Nobel laureate Jennifer Doudna; pioneered NanoCas — the first efficient ultracompact extrahepatic gene editor; partnered with Regeneron for in vivo gene editing.

Epigenome editing company silencing disease-causing genes without permanent DNA cuts; raised $175M Series B led by Hevolution, NEA, and Regeneron Ventures; dosed first patient in Phase 1/2 for chronic hepatitis B with Tune-401.

NextPoint Therapeutics is a clinical-stage immuno-oncology company targeting the HHLA2 checkpoint with two Phase 1 candidates (NPX267, NPX887); raised $122.5M total including $42.5M Series B extension co-led by Catalio in 2024.

Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.

Vizgen is a Cambridge MA life sciences company commercializing MERSCOPE, a spatial genomics platform based on MERFISH technology licensed from Harvard; enables single-cell, subcellular-resolution RNA imaging in intact tissue;

Frontier Medicines is a precision medicine biotech targeting previously undruggable disease-causing proteins using chemoproteomics and covalent chemistry platforms; raised $350M+ in funding including a $257M Series C in 2022;

Synkrino Biotherapeutics uses its AI and Immunology Discovery Engine (AIDE) to identify novel drug targets from immune patient tissue data; targets immune-mediated and inflammatory diseases; early-stage Oakland, CA biotech.

Artiva Biotherapeutics develops off-the-shelf allogeneic natural killer (NK) cell therapies for cancer; lead program AB-101 targets B-cell malignancies and autoimmune disease; raised over $230M including a $150M Series C;